Læknablaðið - 01.09.2014, Blaðsíða 32

S a G a l æ k n i S F R æ ð i n n a R
464 LÆKNAblaðið 2014/100
1. ,,Sigurður Samúelsson fyrrverandi yfirlæknir og pró-
fessor’’. Læknablaðið 1995; 81; Fylgirit 30: 41-7.
2. Epidemiological study of cardiovascular and some other
chronic diseases in Iceland RVK 1969. hjarta.is/uploads/
document/rvkrannsokn.pdf – ágúst 2014.
3. Kristinsson VG. Ólafur landlæknir: endurminningar. Vaka
Helgafell, Reykjavík 1999.
4. Bjornsson OJ, Davidsson D, Olafsson H, Olafsson O,
Sigfusson N, Thorsteinsson Th. Report XVIII. Health
survey in the Reykjavik area—men. Stages I–III, 1967–
1968, 1970–1971 and 1974–1975. Participants, invitation,
response etc. The Icelandic Heart Association, Iceland,
Reykjavik 1979.
5. Bjornsson G, Bjornsson OJ, Davidsson D, Kristjansson
BTh, Olafsson O, Sigfusson N, Thorsteinsson Th.
Report abc XXIV. Health survey in the Reykjavik area—
women. Stages I–III, 1968–1969, 1971–1972 and 1976–1978.
Participants, invitation, response etc. The Icelandic Heart
Association, Iceland, Reykjavik 1982.
6. Sigfusson N. Hjartavernd fjörtíu ára - Yfirlit frá stofunun
landssamtakanna Hjartavernd. Tímarit Hjartaverndar
2004: 39: 6-11.
7. Danesh J, Erqou S, Walker M, Thompson SG, Tipping R,
Ford C, et al. The Emerging Risk Factors Collaboration:
analysis of individual data on lipid, inflammatory and
other markers in over 1.1 million participants in 104
prospective studies of cardiovascular diseases. Eur J
Epidemiol 2007; 22: 839-69. phpc.cam.ac.uk/ceu/rese-
arch/erfc/ - ágúst 2014.
8. Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake
M, Thompson A, et al. Lipid-related markers and cardio-
vascular disease prediction. JAMA 2012; 307: 2499-506.
9. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G,
Wareham N, Bingham S, et al. Triglycerides and the risk
of coronary heart disease: 10,158 incident cases among
262,525 participants in 29 Western prospective studies.
Circulation 2007; 115: 450-8.
10. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai
SRK, Forouhi NG, et al. Markers of dysglycaemia and
risk of coronary heart disease in people without diabetes:
Reykjavik prospective study and systematic review. PLoS
Med 2010; 7: e1000278.
11. Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge
S, Di Angelantonio E, et al. Emerging Risk Factors
Collaboration Diabetes mellitus, fasting blood glucose
concentration, and risk of vascular disease: a collaborative
meta-analysis of 102 prospective studies. Lancet 2010; 375:
2215-22.
12. Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio
E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glu-
cose, and risk of cause-specific death. N Engl J Med 2011;
364: 829-41.
13. Di Angelantonio E, Gao P, Khan H, Butterworth AS,
Wormser D, Kaptoge S, et al. Glycated hemoglobin meas-
urement and prediction of cardiovascular disease. JAMA
2014; 311: 1225-33.
14. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM,
White IR, Gao P, et al. C-reactive protein, fibrinogen, and
cardiovascular disease prediction. N Engl J Med 2012; 367:
1310-20.
15. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB,
Thompson SG, Collins R, et al. C-reactive protein con-
centration and risk of coronary heart disease, stroke, and
mortality: an individual participant meta-analysis. Lancet
2010; 375: 132-40.
16. Psaty BM, O‘Donnell CJ, Gudnason V, Lunetta KL, Folsom
AR, Rotter JI, et al. Cohorts for Heart and Aging Research
in Genomic Epidemiology (CHARGE) Consortium:
Design of prospective meta-analyses of genome-wide
association studies from 5 cohorts. Circ Cardiovasc Genet
2009; 2: 73-80.
17. Thorgeirsson G, Davidsson D, Sigvaldason H, Sigfusson
N. Áhættuþættir kransæðasjúkdóms meðal karla og
kvenna á Íslandi. Niðurstöður úr hóprannsókn Hjarta-
verndar 1967-1985. Læknablaðið 1992; 78: 267-76.
18. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason
V. Estimation of 10-year risk of fatal cardiovascular
disease and coronary heart disease in Iceland with results
comparable with those of the Systematic Coronary Risk
Evaluation project. Eur J Cardiovasc Prev Rehabil 2007; 14:
761-8.
19. Jonsdottir L, Sigfusson N, Gudnason V, Sigvaldason H,
Thorgeirsson G. Do lipids, blood pressure, diabetes, and
smoking confer equal risk of myocardial infarction in
women as in men? The Reykjavik Study. J Cardiovasc Risk
2002; 9: 67-76.
20. Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason
V. Fifteen percent of myocardial infarctions and coronary
revascularizations explained by family history unrelated
to conventional risk factors. The Reykjavik Cohort Study.
Eur Heart J 2002; 23: 1655-63.
21. Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir
II, Stefansdottir I, Sigvaldason H, et al. Breytingar á tíðni
kransæðasjúkdóma á Íslandi. Læknablaðið 2001; 87: 889-
96.
22. Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir
II, Stefansdottir I, Sigvaldason H, et al. Declining coronary
heart disease mortality in Iceland: Contribution by inci-
dence, recurrence and case fatality rate. Scand Cardiovasc
J 2002; 36: 337-41.
23. Sigfusson N, Sigvaldason H, Steingrimsdottir L,
Gudmundsdottir II, Stefansdottir I, Thorsteinsson T, et al.
Decline in ischaemic heart disease in Iceland and change in
risk factor levels. BMJ 1991; 302: 1371-5.
24. Aspelund T, Gudnason V, Magnusdottir BT, Andersen
K, Sigurdsson G, Thorsson B, et al. Analysing the large
decline in coronary heart disease mortality in the Icelandic
population aged 25-74 between the years 1981 and 2006.
PLoS One 2010; 5: e13957.
25. Thorolfsdottir RB, Aspelund T, Capewell S, Critchley J,
Gudnason V, Andersen K. Population assessment of future
trajectories in coronary heart disease mortality. PLoS One
2014; 9: e85800.
26. Sigfusson N, Sigurdsson G, Sigvaldason H, Gudnason V.
Breytingar á reykingavenjum miðaldra og eldri Íslendinga
síðastliðin þrjátíu ár og ástæður þeirra: Niðurstöður úr
hóprannsóknum Hjartaverndar. Læknablaðið 2003; 89:
489-98.
27. Sigfusson N, Sigurdsson G, Aspelund T, Gudnason V.
Skaðleg áhrif reykinga á heilsufar hafa verið verulega
vanmetin: Niðurstöður úr hóprannsóknum Hjartaverndar.
Læknablaðið 2006; 92: 263-9.
28. Sigurdsson G, Sverrisdottir A. Reykingar, dauðans alvara.
Hjartavernd, Kópavogi 2000.
29. Thorgeirsdottir H, Valgeirsdottir H, Gunnarsdottir I,
Gisladottir E, Gunnarsdottir BE, Thorsdottir I, et al. Hvað
borða Íslendingar?: Könnun á mataræði Íslendinga 2010-
2011. Helstu niðurstöður. Directorate of Health, Food and
Veterinary Authority and Unit for Nutrition Research
University of Iceland, Iceland, Reykjavik 2011.
30. Sigfusson N (doctoral thesis). Hypertension in middle-
aged men. The effect of repeated screening and referral to
community physicians on hypertension control. Acta Med
Scand Suppl 1986; 710; 1-131.
31. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ,
Dehghan A, et al. Genome-wide association study of blood
pressure and hypertension. Nat Genet 2009; 41: 677-87.
32. American Heart Association. American Heart Association
notes year›s top research for heart disease and stroke
[press release]. December 22, 2009.
33. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD,
Chasman DI, et al. Genetic variants in novel pathways
influence blood pressure and cardiovascular disease risk.
Nature 2011; 478: 103-9.
34. Thorsson B, Steingrimsdottir L, Halldorsdottir S, Andersen
K, Sigurdsson G, Aspelund T, et al. Changes in total cho-
lesterol levels in Western societies are not related to statin,
but rather dietary factors: the example of the Icelandic
population. Eur Heart J 2013; 34: 1778-82.
35. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan
MJ, Paciorek CJ, et al. National, regional, and global trends
in serum total cholesterol since 1980: systematic analysis of
health examination surveys and epidemiological studies
with 321 country-years and 3·0 million participants. Lancet
2011; 377: 578-86.
36. Thorgeirsdottir H, Steingrimsdottir L, Olafsson O,
Gudna son V. Þróun ofþyngdar og offitu meðal 45-64 ára
Reykvíkinga á árunum 1975-1994. Læknablaðið 2001; 87:
699-704.
37. Bergsveinsson J, Aspelund T, Gudnason V, Benediktsson
R. Algengi sykursýki af tegund tvö á Íslandi 1967-2002.
Læknablaðið 2007; 93: 397-402.
38. Vilbergsson S, Sigurdsson G, Sigvaldason H, Hreidarsson
AB, Sigfusson N. Prevalence and incidence of NIDDM in
Iceland: evidence for stable incidence among males and
females 1967-1991--the Reykjavik Study. Diabet Med 1997;
14: 491-8.
39. Thorsson B, Aspelund T, Harris TB, Launer LJ, Gudnason
V. Þróun holdafars og sykursýki í 40 ár á Íslandi.
Læknablaðið 2009; 95: 259-65.
40. Vilbergsson S, Sigurdsson G, Sigvaldason H, Sigfusson N.
Coronary heart disease mortality amongst non-insulin-
dependent diabetic subjects in Iceland: the independent
effect of diabetes. The Reykjavik Study 17-year follow up.
J Int Med 1998; 244: 309-16.
41. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai
SRK, Forouhi NG, et al. Markers of dysglycaemia and
risk of coronary heart disease in people without diabetes:
Reykjavik prospective study and systematic review. PLoS
Medicine 2010; 7: e1000278.
42. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di
Angelantonio E, et al. Diabetes mellitus, fasting blood
glucose concentration, and risk of vascular disease: a
collaborative meta-analysis of 102 prospective studies.
Lancet 2010; 375: 2215-22.
43. Olafsdottir E, Aspelund T, Sigurdsson G, Thorsson B,
Eiriksdottir G, Harris TB, et al. Effects of statin medication
on mortality risk associated with type 2 diabetes in older
persons: the population-based AGES-Reykjavik Study.
BMJ Open 2011; 1: e000132.
44. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason
V, Hardarson T, Malmberg K, et al. The association
between glucose abnormalities and heart failure in the
population-based Reykjavik study. Diabetes Care 2005; 28:
612-6.
45. Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio
E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glu-
cose, and risk of cause-specific death. N Engl J Med 2011;
364: 829-41.
46. Sigurdsson E, Sigfusson N, Agnarsson U, Sigvaldason
H, Thorgeirsson G. Long-term prognosis of different
forms of coronary heart disease: the Reykjavik Study. Int J
Epidemiol 1995; 24: 58-68.
47. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson
N. Unrecognized myocardial infarction: epidemiology,
clinical characteristics, and the prognostic role of angina
pectoris. The Reykjavik Study. Ann Int Med 1995; 122:
96-102.
48. Jonsdottir LS, Sigfusson N, Sigvaldason H, Thorgeirsson
G. Incidence and prevalence of recognised and unre-
cognised myocardial infarction in women. The Reykjavik
Study. Eur Heart J 1998; 19: 1011-8.
49. Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P,
Aletras AH, et al. Prevalence and prognosis of unrecogni-
zed myocardial infarction determined by cardiac magnetic
resonance in older adults. JAMA 2012; 308: 890-6.
50. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson
U, Thorgeirsson G, Sigfusson N. Predictive value of
apolipoproteins in a prospective survey of coronary artery
disease in men. Am J Cardiol 1992; 69: 1251-4.
51. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G,
Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels
and risk of future coronary heart disease: Large-scale pro-
spective data. Arc Int Med 2008; 168: 598-608.
52. Emerging Risk Factors Collaboration, Erqou S, Kaptoge
S, Perry PL, Di Angelantonio E, Thompson A, et al.
Lipoprotein(a) concentration and the risk of coronary
heart disease, stroke, and nonvascular mortality. JAMA
2009; 302: 412-23.
53. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith
AV, Peloso GM, et al. Genetic Associations with Valvular
Calcification and Aortic Stenosis. N Engl J Med 368: 503-
12.
54. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason
V. Erythrocyte sedimentation rate, an independent pre-
dictor of coronary heart disease in men and women: The
Reykjavik Study. Am J Epidemiol 2003; 158: 844-51.
55. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir
G, Rumley A, et al. C-Reactive Protein and other circulat-
ing markers of inflammation in the prediction of coronary
heart disease. N Engl J Med 2004; 350: 1387-97.
56. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio
E, Shah T, et al. Association between C reactive protein
and coronary heart disease: mendelian randomisation
analysis based on individual participant data. BMJ 2011;
342: d548-d548.
57. Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir
G, Vikingsdottir T, Gudnason V, et al. Mannan binding
lectin as an adjunct to risk assessment for myocardial
infarction in individuals with enhanced risk. J Exp Med
2005; 201: 117-25.
58. Thorarinsson ET, Hardarson T, Vilhjalmsson R,
Sigvaldason H, Sigfusson N. Leit að þáttum er skýra sam-
band menntunar og dánartíðni. Læknablaðið 2000; 86:
91-101.
59. Hardarson T, Gardarsdottir M, Gudmundsson KT, Thor-
geirsson G, Sigvaldason H, Sigfusson N. The relationship
between educational level and mortality. The Reykjavík
Study. J Int Med 2001; 249: 495-502.
60. Rose G. Strategy of prevention: lessons from cardiovas-
cular disease. BMJ 1981; 282: 1847-51.
Heimildir
Fyrsti örvinn við einkennum ofvirkrar þvagblöðruß -
3
Heimildir: 1. Khullar et al. European Urology 63;(2013):283–295.
2. Nitti et al. J Urol 2013;189:1388–1395.
Munnþurrkur sambærilegur
ly�eysu1,2
Það er hægt að lifa við ofvirka
þvagblöðru á annan hátt